Innate Pharma S.A.
NASDAQ:IPHABiotechnology
+$0.03 today
- Market cap
- $115.05M
- Beta
- 0.89
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$0.54
Volume 0.50M
Average 0.07M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Innate Pharma S.A.
NASDAQ:IPHA
Intrinsic Alpha fair value
Locked
Current Price
$1.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -63.6% | +120.9% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -63.6% over three years. Forward estimates point to Revenue at +120.9% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Nuvectis Pharma, Inc. NASDAQ:NVCT | $696.03M | $20.24 | Not rated | -11.2 | +239.87% |
Compugen Ltd. NASDAQ:CGEN | $198.92M | $2.10 | Undervalued | 5.4 | +22.50% |
Molecular Partners AG NASDAQ:MOLN | $112.71M | $2.94 | Not rated | -2.0 | -36.40% |
Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP | $69.86M | $3.39 | Not rated | -1.3 | -76.78% |
Milestone Pharmaceuticals Inc. NASDAQ:MIST | $64.74M | $0.52 | Not rated | -2.5 | -80.24% |
Cardiff Oncology, Inc. NASDAQ:CRDF | $56.49M | $0.73 | Not rated | -1.8 | -58.05% |
Rani Therapeutics Holdings, Inc. NASDAQ:RANI | $34.38M | $0.53 | Not rated | -4.6 | -54.34% |
Elicio Therapeutics, Inc. NASDAQ:ELTX | $28.60M | $1.50 | Not rated | -1.7 | -66.67% |
Continue the stock analysis
Jump to another research area for this company.